Two types of opsonic phagocytosis have been defined depending on the receptor engaged: FcgammaRs mediate type I phagocytosis of IgG-coated particles; complement receptor 3 (CR3) mediates type II phagocytosis of complement-coated particles. In addition to opsonic phagocytosis, CR3 also mediates nonopsonic phagocytosis of zymosan (Z) and Mycobacterium kansasii through engagement of distinct sites. Using Chinese hamster ovary cells stably expressing human CR3, we studied CR3-mediated ingestion of nonopsonized particles, Z or M. kansasii, compared with opsonized zymosan (OZ). We show that 1) while OZ sinks into cells, Z is engulfed by pseudopodia as visualized by electron microscopy; 2) in contrast to OZ, nonopsonic phagocytosis of Z and M. kansasii depends on Rac and Cdc42 but not on Rho activity; and 3) CR3-mediated phagocytosis of Z depends on the kinase activity of the Src family tyrosine kinase Hck, while OZ internalization does not. Therefore, CR3 mediates type I phagocytosis under nonopsonic conditions and type II under opsonic conditions. This is the first evidence that a single receptor can mediate both types of phagocytosis depending on the ligand used.

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.169.4.2003DOI Listing

Publication Analysis

Top Keywords

type phagocytosis
16
mediates type
12
opsonic phagocytosis
12
cr3 mediates
12
phagocytosis
11
complement receptor
8
phagocytosis nonopsonic
8
nonopsonic phagocytosis
8
type
6
receptor cd11b/cd18
4

Similar Publications

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

Denali Therapeutics Inc., South San Francisco, CA, USA.

Background: Macrophages and microglia are myeloid cells that play critical roles in the surveillance of the local environment of the tissues in which they reside. The ability of these phagocytes to perform key functions is contingent on their capacity to sense extracellular cues and mount responses that involve chemotaxis, proliferation, cytokine secretion, and phagocytosis of various cargos for lysosomal clearance. Our overarching hypothesis is that lysosomal degradation of phagocytic cargoes is critical for the resolution of cellular/tissue damage, as well as of inflammation, and that failure to accomplish this step affects myeloid cell states and immune responses.

View Article and Find Full Text PDF

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

PCM Consulting, Pathways Connectivity Maps Inc., Mountain View, CA, USA.

Background: High-throughput assays have attracted significant attention in Alzheimer's Disease (AD) research, especially for enabling rapid diagnostics screening for factors at the molecular level contributing to the disease recurrence. With advances in laboratory automation, there is a growing need for quality pre-clinical data. Assays such as Microarrays, Proteomics, or AI are all dependent on high-quality input data that serve as a starting point.

View Article and Find Full Text PDF

Background: Mitochondrial dysfunction is an early and prominent feature of Alzheimer's disease (AD). We have recently published that lower brain mitochondrial DNA copy number (mtDNAcn) is associated with increased risk of AD neuropathological change and reduced cognitive performance. Here, we addressed how mtDNAcn affects cell-type specific phenotypes.

View Article and Find Full Text PDF

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

Complex Genetics of Alzheimer's Disease group, VIB-UAntwerp Center for Molecular Neurology, Antwerp, Belgium.

Background: ABCA7, an important risk gene for AD, encodes a transporter implicated in lipid transport and phagocytosis, and its disruptions have been linked to AD pathogenesis. However, the impact of these mutations on AD risk is complex due to their interaction with a multifaceted transcriptional architecture and cell type-specificexpression patterns. This study aims to analyze the intricate patterns of ABCA7 expression across diverse cell types, considering various ABCA7 genotypes in relation to AD patients and non-carrier controls, while also exploring the effects of ABCA7 mutations on transcriptome-wide gene expression.

View Article and Find Full Text PDF

Background: Antibodies targeting amyloid beta (Aß) have recently been developed as promising treatments for Alzheimer's Disease (AD). Aducanumab was the first to receive limited FDA approval in 2021 offering much needed new treatment options for AD patients. Aducanumab clears aggregated Aß in the brain, presumably through microglial phagocytosis, although the exact cellular and molecular mechanisms of its effect remain incompletely understood.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!